We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 22% below its sector, cheaper than its peers on earnings.
G&E Herbal Biotechnology Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the innovation and commercialization of advanced botanical extraction technologies and the products derived from them. Its diverse portfolio features a range of botanical anti-aging cosmetic items, including facial foam cleansers, cleansing essences, toners, lightening lotions, essential oils, and moisturizing serums and creams, along with specialized products like the SR-100 botanical essence and bromelain illuminating cleansing mousse. The company also manufactures capsules designed as hepato-protective agents. In the realm of wellness, G&E offers a selection of botanical healthcare products such as ArthrEnergy, Jujubes Polysaccharide, Diabecut, HepatoClean, Astragali Radix, Goji, Prosta, and SR-100 capsules, as well as various products catering to adults. Looking to its future developments, the company is actively pursuing new treatments, including Solarise injection for gynecologic, head, and neck cancers; Apocin capsules intended for non-small cell lung cancer; and SR-T100 Gel, which targets common and genital warts. Beyond its own product lines, G&E Herbal Biotechnology is involved in creating manufacturing technologies for a wide array of dietary supplements and provides expert technical advisory services to other biotechnology organizations. The company was founded in 2002 and is headquartered in Tainan City, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 4911.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
